Survey on Treatment of Chronic Active Cell-Mediated Rejection

Please answer the following questions based on your experience with chronic active cell-mediated rejection (CA CMR) as defined by the Banff 2017 classification (Am J Transplant 2018; 18: 293-307). We are interested only in your treatment of patients with biopsy-proven CA CMR; please do not consider patients whose biopsy showed interstitial inflammation in areas of interstitial fibrosis/tubular atrophy (i-IFTA) not meeting Banff 2017 criteria for CA CMR. The first 3 questions deal with aspects of your transplant center.

Thank you very much for your time and input.